The relevant order of the Ministry of Health No.1038 of May 4 was published on the Ministry’s website.
"To permit clinical trials for a pharmaceutical product intended to implement measures aimed at preventing the occurrence and spread, localization and elimination of coronavirus disease (COVID-19)," the document reads.
According to the annex to the order, a "multicenter randomized study to evaluate the effectiveness of Bioven pharmaceutical product manufactured by the LLC Biopharma Plazma in the complex therapy of patients with pneumonia caused by coronavirus infection COVID-19 / SARS-CoV-2" will be conducted.
The trials will be conducted at Kyiv City Clinical Hospital No.17, Bila Tserkva City Hospital No. 3, Lviv Regional Infectious Diseases Clinical Hospital, Odesa City Infectious Diseases Hospital, and Kyiv City Clinical Hospital No.4.
As of May 6, Ukraine recorded 13,184 coronavirus cases, including 2,097 recoveries and 327 deaths.
Let’s get started read our news at facebook messenger > > > Click here for subscribe